Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy After TAVR
(WorldNews Health)

Contribution To Literature: The GALILEO trial showed that after TAVR, a rivaroxaban-based strategy vs. a clopidogrel-based strategy was associated with excess ischemic and bleeding events. Description: The goal of the trial was to evaluate a rivaroxaban-based strategy compared with a clopidogrel-based strategy among patients who underwent transcatheter aortic valve replacement (TAVR). Study Design Randomized Parallel Open-label Patients were randomized 1-7 days after TAVR to rivaroxaban 10 mg daily/aspirin 75-100 mg daily (n = 826) versus clopidogrel 75 mg daily/aspirin 75-100 mg daily (n = 818). At 90 days, rivaroxaban alone was continued in the experimental group, while aspirin alone was...